Cencora Upgrades 2025 EPS Guidance to $15.85–$16 Amid Specialty Growth

Key Highlights from Cencora’s Q3 2025 Earnings Call

Cencora, Inc. (COR) delivered strong performance during the third quarter of fiscal 2025, with adjusted operating income growing by 21% and adjusted diluted earnings per share (EPS) increasing by 20%. The company raised its fiscal 2025 guidance for the second consecutive time, reflecting confidence in its financial and operational performance. During the call, management outlined three core priorities: enhancing patient care and adherence, strengthening specialty leadership, and leading with market leaders. These goals are supported by strategic investments in pharmaceutical distribution and value-added services.

The CEO, Robert P. Mauch, emphasized Cencora’s leadership in pharmaceutical distribution and its readiness to meet the requirements of the Drug Supply Chain Security Act (DSCSA). He noted that significant investments over the past few years have reinforced the company's role in ensuring patients have efficient, safe, and reliable access to medication. Additionally, he highlighted the integration of Retina Consultants of America (RCA) and preparations for distributing newly approved retina therapies.

Mauch also reiterated the company’s focus on digital transformation, productivity, and targeted investments. He mentioned that areas less aligned with the company’s strategic goals may see reduced investment. James F. Cleary, Executive Vice President and CFO, echoed this sentiment, stating that Cencora’s pharmaceutical-centric strategy and positioning in key markets have allowed it to capitalize on favorable industry trends. His comments were backed by a 20% growth in adjusted diluted EPS, which he attributed to growth-oriented investments in specialty segments.

Outlook and Financial Performance

Cleary announced an updated fiscal 2025 EPS guidance, now expecting earnings to fall between $15.85 and $16, up from the previous range of $15.70 to $15.95. This represents a growth of 15% to 16%. Consolidated revenue growth is now expected to be approximately 9%, with U.S. Healthcare Solutions segment revenue projected to grow between 9% and 10%, down from the previous range of 9% to 11%. International Healthcare Solutions segment revenue is expected to grow between 6% and 7% as-reported, up from 3% to 4%, reflecting currency shifts and sales mix.

Consolidated operating income growth guidance has been raised to 15% to 16%, from 13.5% to 15.5%. U.S. Healthcare Solutions segment operating income is now expected to grow between 20% and 21%, up from 17.5% to 19.5%. However, the international segment operating income is expected to decline by approximately 6% as-reported. Management anticipates that the International Healthcare Solutions segment will return to growth by the end of the fiscal year.

In terms of financial results, consolidated revenue reached $80.7 billion, a 9% increase year-over-year. The U.S. Healthcare Solutions segment reported revenue of $72.9 billion, up 9%, with GLP-1 sales increasing by $1.4 billion or 19% year-over-year. Consolidated gross profit was $2.9 billion, up 21%, with a gross profit margin of 3.55%, an increase of 36 basis points primarily due to the RCA acquisition.

Q&A and Analyst Questions

During the Q&A session, analysts asked about various aspects of Cencora’s performance. James F. Cleary cited biosimilars, both Part D and Part B, moderated GLP-1 growth, and the loss of a grocery customer as factors affecting revenue growth. He also noted that specialty sales continue to support operating income. On the international front, he acknowledged subdued clinical trial activity impacting logistics and consulting but expressed confidence in sequential improvement.

Robert P. Mauch addressed concerns about the integration of RCA and potential policy risks, emphasizing a strong cultural fit and positive customer reaction. He stated that while it is too early to assess the impact of policy changes, Cencora remains actively engaged. When asked about FY26 growth levers, Cleary affirmed confidence in long-term guidance that includes organic operating income growth of 5% to 8% and EPS growth of 8% to 12%.

Sentiment and Market Analysis

Analysts focused on the sustainability of earnings growth, segment drivers, and the integration of RCA. While the tone was generally positive, there was increased interest in understanding the deceleration of GLP-1 growth and the recovery of the international segment. Management maintained a confident and constructive tone, frequently using phrases such as “we are pleased,” “we have confidence,” and “we expect.” In Q&A, they addressed concerns directly without defensiveness, reinforcing their long-term confidence and strategic discipline.

Compared to the previous quarter, the call had more detailed discussions on moderating revenue growth and international headwinds. Guidance for EPS and operating income was raised and narrowed, with the EPS range moving from $15.70–$15.95 to $15.85–$16. U.S. Healthcare Solutions operating income growth guidance increased from 17.5–19.5% to 20–21%.

Risks and Strategic Focus

Management highlighted continued softness in the international segment, particularly in global specialty logistics and consulting, due to subdued clinical trial activity. Cleary noted the loss of a grocery customer in the U.S. segment and moderating GLP-1 growth as factors impacting revenue growth. Mauch addressed the risk of supply chain shortages from tariffs, stating that Cencora is monitoring and educating stakeholders to avoid disruptions.

Analysts raised concerns about potential policy changes, competitive dynamics in specialty distribution, and the impact of slowing GLP-1 growth on future performance. Management is applying “rigorous discipline” to portfolio investments and may deprioritize areas less strategically aligned.

Final Takeaway

Cencora’s Q3 2025 results reflect continued strength in the U.S. Healthcare Solutions segment, robust specialty growth, and successful integration of key acquisitions like RCA. The company raised and narrowed its fiscal 2025 EPS and operating income guidance, while maintaining a focus on digital transformation and disciplined investment. Management remains confident in long-term growth, acknowledging moderating revenue trends in select areas and continued international segment headwinds. Investors received clear signals of ongoing strategic focus and adaptability in the face of evolving market dynamics.